<!doctype html>
<html lang="en"><head>
<meta charset="utf-8"/><meta name="viewport" content="width=device-width,initial-scale=1"/>
<link rel="stylesheet" href="/Newsletter/style.css"/>
<title>Here’s Why ClearBridge Investments Growth Strategy Closed Out Charles River Laboratories International (CRL) — Newsletter</title>
</head><body>
<div class="container">
  <div class="header">
    <h1 style="margin:0;font-size:28px">Newsletter</h1>
    <a class="btn" href="/Newsletter/">Home</a>
  </div>
  <div class="card">
    <h2 style="margin-top:0">Here’s Why ClearBridge Investments Growth Strategy Closed Out Charles River Laboratories International (CRL)</h2>
    <div class="badge">2025-09-17T12:27:40+00:00</div>
    <ul>
      <li>(NYSE:CRL) reported revenue of $1.03 billion in the second quarter of 2025, a 0.6% increase from Q2 2024.</li>
<li>(NYSE:CRL) was 5.00%, and its shares gained 26.44% of their value over the last 52 weeks.</li>
<li>On September 16, 2025, Charles River Laboratories International, Inc.</li>
<li>In addition, please check the fund’s top five holdings to know its best picks in 2025.</li>
<li>US equities significantly rallied in the second quarter, with the S&amp;P 500 returning 10.9%.</li>
<li>As the risk-on sentiment took hold, the benchmark Russell Midcap Growth Index advanced a market-leading 18.2%.</li>
<li>(CRL): Among Mid-Cap Stocks Insiders Were Buying in Q1 2025 Charles River Laboratories International, Inc.</li>
    </ul>
    <p>
      <a class="btn" href="https://twitter.com/intent/tweet?text=Here’s Why ClearBridge Investments Growth Strategy Closed Out Charles River Laboratories International (CRL)
• (NYSE:CRL) reported revenue of $1.03 billion in the second quarter of 2025, a 0.6% increase from Q2 2024.
• (NYSE:CRL) was 5.00%, and its shares gained 26.44% of their value over the last 52 weeks.
• On September 16, 2025, Charles River Laboratories International, Inc.
• In addition, please check the fund’s top five holdings to know its best picks in 2025.
• US equities significantly rallied in the second quarter, with the S&amp;P 500 returning 10.9%.
• As the risk-on sentiment took hold, the benchmark Russell Midcap Growth Index advanced a market-leading 18.2%.
• (CRL): Among Mid-Cap Stocks Insiders Were Buying in Q1 2025 Charles River Laboratories International, Inc." target="_blank" rel="noopener">Tweet bullets</a>
      &nbsp;&nbsp;<a class="btn" href="https://finance.yahoo.com/news/why-clearbridge-investments-growth-strategy-122740531.html" target="_blank" rel="noopener nofollow">finance.yahoo.com</a>
    </p>
  </div>
  <div class="footer">Built from digest_5bullets.md</div>
</div>
</body></html>